Glycoxidised LDL isolated from subjects with impaired glucose tolerance increases CD36 and peroxisome proliferator-activator receptor γ gene expression in macrophages

Diabetologia

Volumn 50, Issue 5, 2007, Pages 1080-1088

  Graessler, J ^a   Pietzsch, J ^b   Westendorf, T ^a   Julius, U ^a   Bornstein, S R ^a   Kopprasch, S ^a  

^a DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^b INSTITUTE OF ION BEAM PHYSICS AND MATERIALS RESEARCH   (Germany)

Author keywords

Advanced glycosylation end products; CD36; Gene expression; Glycoxidation; Humans; Impaired glucose tolerance; LDL; Macrophage; PPAR scavenger receptor

Indexed keywords

6 N CARBOXYMETHYLLYSINE; APOLIPOPROTEIN B100; ARGININE; CD36 ANTIGEN; DIAMINO ACID; LOW DENSITY LIPOPROTEIN; LYSINE; MESSENGER RNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROLINE; SCAVENGER RECEPTOR; TYROSINE;

ADULT; ARTICLE; ATHEROGENESIS; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; FEMALE; GAS CHROMATOGRAPHY; GENE EXPRESSION; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INCUBATION TIME; MACROPHAGE; MALE; MASS SPECTROMETRY; OXIDATION; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ADULT; ANTIGENS, CD; ANTIGENS, CD36; BLOOD GLUCOSE; FEMALE; GENE EXPRESSION REGULATION; GLUCOSE INTOLERANCE; HUMANS; LIPOPROTEINS, LDL; MACROPHAGES; MALE; MIDDLE AGED; PPAR GAMMA; REFERENCE VALUES;

EID: 34147151756     PISSN: 0012186X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00125-007-0645-9     Document Type: Article

References (42)

1. Kopprasch S, Pietzsch J, Kuhlisch E et al (2002) In vivo evidence for increased oxidation of circulating LDL in impaired glucose tolerance. Diabetes 51:3102-3106
2. Chisolm GM, Steinberg D (2000) The oxidative modification hypothesis of atherogenesis: an overview. Free Radic Biol Med 28:1815-1826
3. Nagy L, Tontonoz P, Alvarez JG, Chen H, Evans RM (1998) Oxidized LDL regulates macrophage gene expression through ligand activation of PPARgamma. Cell 93:229-240
4. Han KH, Chang MK, Boullier A et al (2000) Oxidized LDL reduces monocyte CCR2 expression through pathways involving peroxisome proliferator-activated receptor gamma. J Clin Invest 106:793-802
5. Jiang C, Ting AT, Seed B (1998) PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines. Nature 391:82-86
6. Veiraiah A (2005) Hyperglycemia, lipoprotein glycation, and vascular disease. Angiology 56:431-438
7. Schleicher E, Weigert C, Rohrbach H, Nerlich A, Bachmeier B, Friess U (2005) Role of glucoxidation and lipid oxidation in the development of atherosclerosis. Ann N Y Acad Sci 1043:343-354
8. ε-(carboxymethyl) lysine is impaired in mice deficient in NADPH oxidase: a role for phagocyte-derived oxidants in the formation of advanced glycation end products during inflammation. Diabetes 52:2137-2143
9. Nakagawa T, Nozaki S, Nishida M et al (1998) Oxidized LDL increases and interferon-gamma decreases expression of CD36 in human monocyte-derived macrophages. Arterioscler Thromb Vasc Biol 18:1350-1357
10. Feng J, Han J, Pearce SF et al (2000) Induction of CD36 expression by oxidized LDL and IL-4 by a common signaling pathway dependent on protein kinase C and PPAR-gamma. J Lipid Res 41:688-696
11. Westendorf T, Graessler J, Kopprasch S (2005) Hypochlorite-oxidized low-density lipoprotein upregulates CD36 and PPARgamma mRNA expression and modulates SR-BI gene expression in murine macrophages. Mol Cell Biochem 277:143-152
12. Lam MC, Tan KC, Lam KS (2004) Glycoxidized low-density lipoprotein regulates the expression of scavenger receptors in THP-1 macrophages. Atherosclerosis 177:313-320
13. Brown BE, Dean RT, Davies MJ (2005) Glycation of low-density lipoproteins by methylglyoxal and glycolaldehyde gives rise to the in vitro formation of lipid-laden cells. Diabetologia 48:361-369 14
14. Hanefeld M, Chiasson JL, Koehler C, Henkel E, Schaper F, Temelkova-Kurktschiev T (2004) Acarbose slows progression of intima-media thickness of the carotid arteries in subjects with impaired glucose tolerance. Stroke 35:1073-1078
15. Pietzsch J, Subat S, Nitzsche S, Leonhardt W, Schentke KU, Hanefeld M (1995) Very fast ultracentrifugation of serum lipoproteins: influence on lipoprotein separation and composition. Biochim Biophys Acta 1254:77-88
16. Requena JR, Chao CC, Levine RL, Stadtman ER (2001) Glutamic and aminoadipic semialdehydes are the main carbonyl products of metal-catalyzed oxidation of proteins. Proc Natl Acad Sci U S A 98:69-74
17. Pietzsch J, Bergmann R, Kopprasch S (2004) Analysis of nonprotein amino acids as specific markers of low density lipoprotein apolipoprotein B-100 oxidation in human atherosclerotic lesions: the use of N(O)-ethoxycarbonyl trifluoroethyl ester derivatives and GC-MS. Spectroscopy 18:177-183
18. Berliner JA, Heinecke JW (1996) The role of oxidized lipoproteins in atherogenesis. Free Radic Biol Med 20:707-727
19. Tontonoz P, Nagy L (1999) Regulation of macrophage gene expression by peroxisome-proliferator-activated receptor gamma: implications for cardiovascular disease. Curr Opin Lipidol 10:485-490
20. Fu MX, Requena JR, Jenkins AJ, Lyons TJ, Baynes JW, Thorpe SR (1996) The advanced glycation end product, Nε-(carboxymethyl) lysine, is a product of both lipid peroxidation and glycoxidation reactions. J Biol Chem 271:9982-9986
21. Pietzsch J, Lattke P, Julius U (2000) Oxidation of apolipoprotein B-100 in circulating LDL is related to LDL residence time. In vivo insights from stable-isotope studies. Arterioscler Thromb Vasc Biol 20:E63-E67
22. Malle E, Marsche G, Arnhold J, Davies MJ (2006) Modification of low-density lipoprotein by myeloperoxidase-derived oxidants and reagent hypochlorous acid. Biochim Biophys Acta 1761:392-415
23. Brennan ML, Penn MS, Van Lente F et al (2003) Prognostic value of myeloperoxidase in patients with chest pain. N Engl J Med 349:1595-1604
24. Itabe H (2003) Oxidized low-density lipoproteins: what is understood and what remains to be clarified. Biol Pharm Bull 26:1-9
25. Knott HM, Brown BE, Davies MJ, Dean RT (2003) Glycation and glycoxidation of low-density lipoproteins by glucose and low-molecular mass aldehydes. Formation of modified and oxidized particles. Eur J Biochem 270:3572-3582
26. Pietzsch J, Bergmann R, Wuest F, Pawelke B, Hultsch C, van den Hoff J (2005) Catabolism of native and oxidized low density lipoproteins: in vivo insights from small animal positron emission tomography studies. Amino Acids 29:389-404
27. Sasaki J, Cottam GL (1982) Glycosylation of LDL decreases its ability to interact with high-affinity receptors of human fibroblasts in vitro and decreases its clearance from rabbit plasma in vivo. Biochim Biophys Acta 713:199-207
28. Nicholson AC (2004) Expression of CD36 in macrophages and atherosclerosis: the role of lipid regulation of PPARgamma signaling. Trends Cardiovasc Med 14:8-12
29. Kunjathoor VV, Febbraio M, Podrez EA et al (2002) Scavenger receptors class A-I/II and CD36 are the principal receptors responsible for the uptake of modified low density lipoprotein leading to lipid loading in macrophages. J Biol Chem 277:49982-49988
30. Moore KJ, Kunjathoor VV, Koehn SL et al (2005) Loss of receptor-mediated lipid uptake via scavenger receptor A or CD36 pathways does not ameliorate atherosclerosis in hyperlipidemic mice. J Clin Invest 115:2192-2201
31. Babaev VR, Gleaves LA, Carter KJ et al (2000) Reduced atherosclerotic lesions in mice deficient for total or macrophagespecific expression of scavenger receptor-A. Arterioscler Thromb Vasc Biol 20:2593-2599
32. Febbraio M, Podrez EA, Smith JD et al (2000) Targeted disruption of the class B scavenger receptor CD36 protects against atherosclerotic lesion development in mice. J Clin Invest 105:1049-1056
33. Moore KJ, Rosen ED, Fitzgerald ML et al (2001) The role of PPAR-gamma in macrophage differentiation and cholesterol uptake. Nat Med 7:41-47
34. Chawla A, Boisvert WA, Lee CH et al (2001) A PPAR gamma-LXR-ABCA1 pathway in macrophages is involved in cholesterol efflux and atherogenesis. Mol Cell 7:161-171
35. Gosling J, Slaymaker S, Gu L et al (1999) MCP-1 deficiency reduces susceptibility to atherosclerosis in mice that overexpress human apolipoprotein B. J Clin Invest 103:773-778
36. Li AC, Binder CJ, Gutierrez A et al (2004) Differential inhibition of macrophage foam-cell formation and atherosclerosis in mice by PPARalpha, beta/delta, and gamma. J Clin Invest 114:1564-1576
37. Collins AR, Meehan WP, Kintscher U et al (2001) Troglitazone inhibits formation of early atherosclerotic lesions in diabetic and nondiabetic low density lipoprotein receptor-deficient mice. Arterioscler Thromb Vasc Biol 21:365-371
38. Van Eck M, Bos IS, Hildebrand RB, Van Rij BT, Van Berkel TJ (2004) Dual role for scavenger receptor class B, type I on bone marrow-derived cells in atherosclerotic lesion development. Am J Pathol 165:785-794
39. Chinetti G, Gbaguidi FG, Griglio S et al (2000) CLA-1/SR-BI is expressed in atherosclerotic lesion macrophages and regulated by activators of peroxisome proliferator-activated receptors. Circulation 101:2411-2417
40. Han J, Nicholson AC, Zhou X, Feng J, Gotto AM Jr, Hajjar DP (2001) Oxidized low density lipoprotein decreases macrophage expression of scavenger receptor B-I. J Biol Chem 276:16567-16572
41. Hirano K, Yamashita S, Nakagawa Y et al (1999) Expression of human scavenger receptor class B type I in cultured human monocyte-derived macrophages and atherosclerotic lesions. Circ Res 85:108-116
42. Scott J (1989) The molecular and cell biology of apolipoprotein-B. Mol Biol Med 6:65-80